Recent Investment Analysts’ Ratings Updates for Palomar (PLMR)

Palomar (NASDAQ: PLMR) has recently received a number of price target changes and ratings updates:

• 4/22/2026 – Palomar was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.
• 4/16/2026 – Palomar was upgraded by Zacks Research from “hold” to “strong-buy”.
• 4/7/2026 – Palomar was downgraded by Weiss Ratings from “buy (b-)” to “hold (c+)”.
• 4/7/2026 – Palomar had its price target raised by Keefe, Bruyette & Woods from $183.00 to $186.00. They now have an “outperform” rating on the stock.
• 3/1/2026 – Palomar was downgraded by Wall Street Zen from “buy” to “hold”.
• 2/23/2026 – Palomar had its price target raised by JPMorgan Chase & Co. from $155.00 to $160.00. They now have an “overweight” rating on the stock.

Insider Activity at Palomar

In other news, CEO Mac Armstrong sold 3,500 shares of the firm’s stock in a transaction dated Tuesday, April 21st. The stock was sold at an average price of $130.77, for a total value of $457,695.00. Following the completion of the transaction, the chief executive officer directly owned 336,388 shares in the company, valued at $43,989,458.76. This trade represents a 1.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO T Christopher Uchida sold 783 shares of Palomar stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $128.04, for a total value of $100,255.32. Following the sale, the chief financial officer directly owned 14,752 shares of the company’s stock, valued at $1,888,846.08. This trade represents a 5.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 65,132 shares of company stock worth $7,989,780 in the last quarter. 3.70% of the stock is currently owned by company insiders.

Palomar Holdings, Inc (NASDAQ: PLMR) is a specialty insurance holding company focused on providing medical stop-loss coverage and related administrative services to self-funded employer health plans in the United States. The firm operates through two primary business segments—Medical Stop-Loss and Specialty Program Management—to deliver tailored risk protection and comprehensive program administration.

In its Medical Stop-Loss segment, Palomar underwrites excess and aggregate stop-loss policies designed to shield self-insured employers from catastrophic medical claims that exceed pre-determined retention levels.